

Special Issue

Advances of Particle Therapy in Prostate Cancer

Message from the Guest Editor

Prostate cancer is the most prevalent cancer among men in the United States. Radiation therapy has been one of the major treatment options for prostate cancer. Recent technical advances in external beam RT using photons—for example, SBRT and IMRT—have permitted the delivery of a higher dose to tumors and a lower dose to surrounding tissues. At the same time, basic and clinical research into external RT using particles (particle RT) has been carried out for the purpose of establishing more effective and non-invasive treatments. Among the particles used in such treatments, protons and carbon ions are the ones most commonly used. New technologies and clinical approaches have been developed to improve therapies. This Special Issue aims to introduce recent advances and breakthroughs in the particle treatment of prostate cancer. Submissions of communications, full papers, mini-reviews, and reviews are all welcomed. We look forward to your contributions and fruitful discussions.

Guest Editor

Dr. Xinning Wang

Department of Biomedical Engineering, Case School of Engineering,
Case Western Reserve University, Cleveland, OH, USA

Deadline for manuscript submissions

closed (10 September 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/164411

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)